Research programme: alpha7 nicotinic acetylcholine receptor modulator therapeutics - Bionomics/Merck

Drug Profile

Research programme: alpha7 nicotinic acetylcholine receptor modulator therapeutics - Bionomics/Merck

Alternative Names: BNC 1881; BNC 375

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Bionomics
  • Class Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders

Most Recent Events

  • 23 Jun 2014 Bionomics and Merck enter into an exclusive research collaboration and license agreement for BNC375 programme for Cognition disorders associated with Alzheimer's disease and other CNS disorders
  • 04 Feb 2013 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by Bionomics
  • 17 Dec 2012 Bionomics announces name of its lead candidate molecule
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top